← All trials
NCT07128251
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 20, 2025
- Primary completion
- Jan 30, 2028
- Completion date
- Dec 30, 2029
- First posted
- Aug 17, 2025
- Last posted
- Aug 17, 2025
- Enrollment
- 47
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Anhui Medical UniversityLead sponsor
- Anhui Medical UniversitySponsor investigator
- Shaanxi Provincial People's HospitalCollaborator
- Xi'an International Medical Center HospitalCollaborator
- Harbin Medical UniversityCollaborator
- Hacettepe UniversityCollaborator
- Henan Provincal People's HospitalCollaborator
- Shandong UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.